Novo Nordisk A/S’s obesity drug Wegovy will be an option for about 1.2 million more patients in England’s National Health Service, after the drug price regulator recommended it to prevent heart attacks and strokes.
www.bloomberg.com
#Novos #Wegovy #Offered #Widely #Englands #NHS
Novo’s Wegovy to Be Offered Far More Widely on England’s NHS
